New scan could spot hidden blood clots without needles or surgery
NCT ID NCT03830320
First seen Feb 28, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This early-stage study is testing a new radioactive tracer called 64Cu-FBP8 that lights up blood clots on a special PET-MR scan. Researchers want to see if it can safely and accurately detect clots in people with atrial fibrillation, COVID-19, or cancer. The study involves 165 participants and aims to find a non-invasive alternative to current clot-detection methods.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
64Cu-FBP8 (a radioactive tracer)
What this could lead to
If successful, this could provide a safer, whole-body scan to detect dangerous blood clots without invasive procedures.
What could go wrong
This is a very early Phase 1 study focused on safety and imaging accuracy. The tracer may not prove reliable enough for routine use, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.